🔗 Share this article

As the US undertakes historic revisions to its immunization guidelines, an unexpected name appears in a surprising turn: Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccines throughout the pandemic and has concentrated on potential fatalities after Covid immunization in her brief position at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Schedule

Health officials had intended to unveil major revisions to the pediatric immunization program earlier this month, bringing the US with the Danish vaccine program, according to reports – a major change that would put the US at odds with many the international standard with insufficient data for public health gain. This reveal has been delayed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the agency – and it suggests a greater focus upon rolling back long-standing vaccines at the FDA.

Høeg has repeatedly called for ending certain pediatric vaccine recommendations in the US so as to align more like the Danish model, a nation with universal health coverage and a population approximately the size of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccines – typically the domain of Dr. Prasad, director of the FDA’s vaccine center – rather than medication approval.

Questions Over Expertise

Dr. Høeg has no obvious track record in drug development, oversight or management, which has been standard for former heads of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since March.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in leading a major agency. She has no expertise in pharmaceutical oversight.”

Past heads of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Frankly, she lacks the type of experience that previous people who ran CBER have had.”

CDER has an immense workload at the FDA, Woodcock emphasized.

“The public just pays attention on the novel medication approvals, but the generic program authorizes numerous generic drugs. There is also a biosimilars division, over-the-counter program and so forth, and every single one need to be managed,” Dr. Woodcock noted. “The area you neglect, that is the part that I always told people is going to cause problems.”

Furthermore, a major management component to the position, which supervises over 5,000 employees. “It is a massive leadership role, if you execute it properly,” she concluded.

Response and Contentious Programs

Regarding questions about Høeg’s qualifications and whether this selection signifies more teamwork among regulatory chiefs on immunizations, a representative stated that the “inquiries are based on flawed assumptions”.

“Her resume matches the responsibilities of her job,” the spokesperson explained, pointing to the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial one-day drug-approval program that allegedly concerned her predecessors. “How are these drugs being picked for this expedited pathway? Who makes the calls?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards more relaxed regulations of pharmaceuticals, aside from immunizations.”

Public Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if problematic, past, Howard said. She authored a study using non-validated public submissions to determine the rate of heart inflammation after COVID-19 immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccinations are more dangerous than they are.

Among her “policy goals” for the current federal leadership included revising guidelines for new vaccines and ending “non-essential” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has allegedly proposed excluding adolescent males from receiving COVID-19 vaccinations.

“She is an complete ideologue who commences with her preconceived notions and tailors the evidence to fit the science in a highly disingenuous, fraudulent manner,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|